Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 577

1.

Inhibition of CD95/CD95L Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 Feb 16. pii: molcanres.0563.2017. doi: 10.1158/1541-7786.MCR-17-0563. [Epub ahead of print]

PMID:
29453321
2.

Human Milk Oligosaccharides as Promising Antivirals.

Morozov V, Hansman G, Hanisch FG, Schroten H, Kunz C.

Mol Nutr Food Res. 2018 Jan 16. doi: 10.1002/mnfr.201700679. [Epub ahead of print] Review.

PMID:
29336526
3.

Facial asymmetry correction with moulded helmet therapy in infants with deformational skull base plagiocephaly.

Kreutz M, Fitze B, Blecher C, Marcello A, Simon R, Cremer R, Zeilhofer HF, Kunz C, Mayr J.

J Craniomaxillofac Surg. 2018 Jan;46(1):28-34. doi: 10.1016/j.jcms.2017.10.013. Epub 2017 Oct 16.

PMID:
29221913
4.

Freeze-Drying From Organic Cosolvent Systems, Part 1: Thermal Analysis of Cosolvent-Based Placebo Formulations in the Frozen State.

Kunz C, Schuldt-Lieb S, Gieseler H.

J Pharm Sci. 2018 Mar;107(3):887-896. doi: 10.1016/j.xphs.2017.11.003. Epub 2017 Nov 10.

PMID:
29133233
5.

Formation and Properties of Laser-Induced Periodic Surface Structures on Different Glasses.

Gräf S, Kunz C, Müller FA.

Materials (Basel). 2017 Aug 10;10(8). pii: E933. doi: 10.3390/ma10080933.

6.

Compositional Analysis and Metabolism of Human Milk Oligosaccharides in Infants.

Kunz C, Rudloff S.

Nestle Nutr Inst Workshop Ser. 2017;88:137-147. doi: 10.1159/000455398. Epub 2017 Mar 27. Review.

PMID:
28346931
7.

Osteo-Odonto-Keratoprosthesis in Severe Ocular Graft versus Host Disease.

Plattner K, Goldblum D, Halter J, Kunz C, Koeppl R, Gerber-Hollbach N.

Klin Monbl Augenheilkd. 2017 Apr;234(4):455-456. doi: 10.1055/s-0042-123148. Epub 2017 Mar 22. No abstract available.

PMID:
28329888
8.

Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.

Beisel C, Benner A, Kunz C, Kopp-Schneider A.

Biom J. 2017 May;59(3):511-530. doi: 10.1002/bimj.201600047. Epub 2017 Mar 6.

PMID:
28263395
9.

In Vitro, Ex Vivo, and In Vivo Activities of Diamidines against Trypanosoma congolense and Trypanosoma vivax.

Gillingwater K, Kunz C, Braghiroli C, Boykin DW, Tidwell RR, Brun R.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02356-16. doi: 10.1128/AAC.02356-16. Print 2017 May.

10.

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Endris V, Kirchner M, Stenzinger A, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. doi: 10.1182/blood-2016-09-738161. Epub 2017 Jan 24.

PMID:
28119329
11.

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations.

Kunz CU, Stallard N, Parsons N, Todd S, Friede T.

Biom J. 2017 Mar;59(2):344-357. doi: 10.1002/bimj.201500233. Epub 2016 Nov 25.

12.

Neutral oligosaccharides in feces of breastfed and formula-fed infants at different ages.

Dotz V, Adam R, Lochnit G, Schroten H, Kunz C.

Glycobiology. 2016 Dec;26(12):1308-1316. Epub 2016 Sep 9.

PMID:
27613801
13.

Influence of Gestational Age, Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human Milk.

Kunz C, Meyer C, Collado MC, Geiger L, García-Mantrana I, Bertua-Ríos B, Martínez-Costa C, Borsch C, Rudloff S.

J Pediatr Gastroenterol Nutr. 2017 May;64(5):789-798. doi: 10.1097/MPG.0000000000001402.

PMID:
27602704
14.

First Total Synthesis, Structure Revision, and Natural History of the Smallest Cytochalasin: (+)-Periconiasin G.

Zaghouani M, Kunz C, Guédon L, Blanchard F, Nay B.

Chemistry. 2016 Oct 17;22(43):15257-15260. doi: 10.1002/chem.201603734. Epub 2016 Sep 9.

PMID:
27556729
15.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

16.

Myeloid cells do not contribute to gender-dependent differences in disease outcome in murine cutaneous leishmaniasis.

Fischer MR, Kunz C, Dietze-Schwonberg K, Lorenz B, von Stebut E.

Cell Immunol. 2016 Oct;308:13-18. doi: 10.1016/j.cellimm.2016.07.009. Epub 2016 Jul 15.

PMID:
27444131
17.

Inhibition of Low-Grade Inflammation by Anthocyanins after Microbial Fermentation in Vitro.

Kuntz S, Kunz C, Domann E, Würdemann N, Unger F, Römpp A, Rudloff S.

Nutrients. 2016 Jul 2;8(7). pii: E411. doi: 10.3390/nu8070411.

18.

Bio-Inspired Functional Surfaces Based on Laser-Induced Periodic Surface Structures.

Müller FA, Kunz C, Gräf S.

Materials (Basel). 2016 Jun 15;9(6). pii: E476. doi: 10.3390/ma9060476. Review.

19.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

20.

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Borghardt JM, Weber B, Staab A, Kunz C, Kloft C.

Br J Clin Pharmacol. 2016 Sep;82(3):739-53. doi: 10.1111/bcp.12999. Epub 2016 Jun 23.

21.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.

22.

Effects of the neurokinin-1 antagonist maropitant on canine gastric emptying assessed by radioscintigraphy and breath test.

Schmitz S, Fink T, Failing K, Borsch C, Kunz C, Clemence R, Savary-Bataille K, Neiger R.

Tierarztl Prax Ausg K Kleintiere Heimtiere. 2016 Jun 16;44(3):163-9. doi: 10.15654/TPK-150039. Epub 2016 Apr 19.

PMID:
27090486
23.

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D.

Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

24.

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.

Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 18;11:585-95. doi: 10.2147/COPD.S94234. eCollection 2016.

25.

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S.

Br J Haematol. 2016 Jul;174(1):127-35. doi: 10.1111/bjh.14038. Epub 2016 Mar 15.

PMID:
26991959
26.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

27.

FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk.

Sprenger N, Odenwald H, Kukkonen AK, Kuitunen M, Savilahti E, Kunz C.

Eur J Nutr. 2017 Apr;56(3):1293-1301. doi: 10.1007/s00394-016-1180-6. Epub 2016 Feb 24.

PMID:
26907090
28.

Femtosecond laser-induced surface structures on carbon fibers.

Sajzew R, Schröder J, Kunz C, Engel S, Müller FA, Gräf S.

Opt Lett. 2015 Dec 15;40(24):5734-7. doi: 10.1364/OL.40.005734.

PMID:
26670499
29.

Inhibition of pancreatic cancer cell migration by plasma anthocyanins isolated from healthy volunteers receiving an anthocyanin-rich berry juice.

Kuntz S, Kunz C, Rudloff S.

Eur J Nutr. 2017 Feb;56(1):203-214. doi: 10.1007/s00394-015-1070-3. Epub 2015 Oct 17.

PMID:
26476633
30.

Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.

Borghardt JM, Weber B, Staab A, Kunz C, Formella S, Kloft C.

Br J Clin Pharmacol. 2016 Mar;81(3):538-52. doi: 10.1111/bcp.12780. Epub 2016 Feb 17.

31.

Reply to R. Warsame et al.

Bochtler T, Hegenbart U, Kunz C, Benner A, Schönland SO.

J Clin Oncol. 2015 Nov 20;33(33):3976-7. doi: 10.1200/JCO.2015.63.2141. Epub 2015 Aug 31. No abstract available.

PMID:
26324370
32.

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.

Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 20;10:1673-83. doi: 10.2147/COPD.S86002. eCollection 2015.

33.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J.

Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29.

PMID:
26215436
34.

Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Stallard N, Kunz CU, Todd S, Parsons N, Friede T.

Stat Med. 2015 Oct 15;34(23):3104-15. doi: 10.1002/sim.6567. Epub 2015 Jun 26.

35.

Two-stage phase II oncology designs using short-term endpoints for early stopping.

Kunz CU, Wason JM, Kieser M.

Stat Methods Med Res. 2017 Aug;26(4):1671-1683. doi: 10.1177/0962280215585819. Epub 2015 Jun 2.

PMID:
26037529
36.

Computer-assisted virtual planning and surgical template fabrication for frontoorbital advancement.

Soleman J, Thieringer F, Beinemann J, Kunz C, Guzman R.

Neurosurg Focus. 2015 May;38(5):E5. doi: 10.3171/2015.3.FOCUS14852.

PMID:
25929967
37.

Emergence of tick-borne encephalitis in new endemic areas in Austria: 42 years of surveillance.

Heinz FX, Stiasny K, Holzmann H, Kundi M, Sixl W, Wenk M, Kainz W, Essl A, Kunz C.

Euro Surveill. 2015 Apr 2;20(13):9-16.

38.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.

39.

Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma.

Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, Schmitt M.

Haematologica. 2015 Jul;100(7):e285-8. doi: 10.3324/haematol.2014.116772. Epub 2015 Mar 27. No abstract available.

40.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
41.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
42.

Uptake and bioavailability of anthocyanins and phenolic acids from grape/blueberry juice and smoothie in vitro and in vivo.

Kuntz S, Rudloff S, Asseburg H, Borsch C, Fröhling B, Unger F, Dold S, Spengler B, Römpp A, Kunz C.

Br J Nutr. 2015 Apr 14;113(7):1044-55. doi: 10.1017/S0007114515000161. Epub 2015 Mar 17.

PMID:
25778541
43.
44.

Cone-beam computed tomography for planning and assessing surgical outcomes of osteo-odonto-keratoprosthesis.

Berg BI, Dagassan-Berndt D, Goldblum D, Kunz C.

Cornea. 2015 Apr;34(4):482-5. doi: 10.1097/ICO.0000000000000382.

PMID:
25710508
45.

Inhibition of low-grade inflammation by anthocyanins from grape extract in an in vitro epithelial-endothelial co-culture model.

Kuntz S, Asseburg H, Dold S, Römpp A, Fröhling B, Kunz C, Rudloff S.

Food Funct. 2015 Apr;6(4):1136-49. doi: 10.1039/c4fo00755g.

PMID:
25690135
46.

The Comprehensive AOCMF Classification System: Glossary of Common Terminology.

Cornelius CP, Audigé L, Kunz C, Prein J.

Craniomaxillofac Trauma Reconstr. 2014 Dec;7(Suppl 1):S136-40. doi: 10.1055/s-0034-1390072. No abstract available.

47.

The Comprehensive AOCMF Classification System: Fracture Case Collection, Diagnostic Imaging Work Up, AOCOIAC Iconography and Coding.

Cornelius CP, Kunz C, Neff A, Kellman RM, Prein J, Audigé L.

Craniomaxillofac Trauma Reconstr. 2014 Dec;7(Suppl 1):S131-5. doi: 10.1055/s-0034-1393722.

48.

The Comprehensive AOCMF Classification System: Radiological Issues and Systematic Approach.

Buitrago-Téllez CH, Cornelius CP, Prein J, Kunz C, di Ieva A, Audigé L.

Craniomaxillofac Trauma Reconstr. 2014 Dec;7(Suppl 1):S123-30. doi: 10.1055/s-0034-1389565.

49.

The Comprehensive AOCMF Classification System: Classification and Documentation within AOCOIAC Software.

Audigé L, Cornelius CP, Kunz C, Buitrago-Téllez CH, Prein J.

Craniomaxillofac Trauma Reconstr. 2014 Dec;7(Suppl 1):S114-22. doi: 10.1055/s-0034-1389564.

50.

The Comprehensive AOCMF Classification System: Orbital Fractures - Level 3 Tutorial.

Kunz C, Audigé L, Cornelius CP, Buitrago-Téllez CH, Rudderman R, Prein J.

Craniomaxillofac Trauma Reconstr. 2014 Dec;7(Suppl 1):S092-102. doi: 10.1055/s-0034-1389562.

Supplemental Content

Support Center